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Introduction {#ehf212262-sec-0004}
============

The risk of stroke in atrial fibrillation (AF) varies in relation to age and comorbidity, as reflected in the CHA~2~DS~2~‐VASc stroke risk assessment scheme.[1](#ehf212262-bib-0001){ref-type="ref"} CHA~2~DS~2~‐VASc counts one point for chronic heart failure (CHF), mainly based on an observation of increased stroke risk among patients with recent heart failure in the Stroke Prevention in Atrial Fibrillation trial[2](#ehf212262-bib-0002){ref-type="ref"} from 1992. An early meta‐analysis of five studies in 1994 also showed a trend, although not significant, towards higher stroke risk in AF patients with heart failure.[3](#ehf212262-bib-0003){ref-type="ref"}

The inclusion of points for heart failure in CHA~2~DS~2~‐VASc was inherited from the older CHADS~2~ scheme where it was helpful in predicting stroke risk.[4](#ehf212262-bib-0004){ref-type="ref"} In the more inclusive CHA~2~DS~2~‐VASc score, heart failure is accompanied by the five most important predictors for incident heart failure according to a recent long‐term follow‐up study by the Framingham Heart Study, namely, previous myocardial infarction, ischaemic heart disease, diabetes mellitus, age, and hypertension.[5](#ehf212262-bib-0005){ref-type="ref"}

In more recent studies, heart failure has not emerged as an independent risk factor or else been rated as a very weak factor compared with the other components of the stroke risk scores.[6](#ehf212262-bib-0006){ref-type="ref"}, [7](#ehf212262-bib-0007){ref-type="ref"}, [8](#ehf212262-bib-0008){ref-type="ref"}

Our aim was therefore to test the hypothesis that heart failure is a risk factor for stroke, independent of other risk factors in the CHA~2~DS~2~‐VASc score.

Methods {#ehf212262-sec-0005}
=======

We conducted a retrospective cohort study of data from Swedish health registers maintained by the Swedish Board of Health and Welfare.[9](#ehf212262-bib-0009){ref-type="ref"} All 325 020 patients with a diagnosis of AF in the Swedish Patient Register between 1 July 2005 and 31 December 2011 were identified. Exclusions were made of patients ≤20 years of age (*n* = 367), of patients with valvular AF defined as mitral stenosis or mechanical heart valve (*n* = 7804), and of patients who died within 30 days of the index contact (*n* = 16 317). After exclusions, 300 839 patients remained for the study (flow chart, *Figure* [*1*](#ehf212262-fig-0001){ref-type="fig"}).

![Inclusions and exclusions of study patients. AF, atrial fibrillation.](EHF2-5-231-g001){#ehf212262-fig-0001}

Index date was defined as the date of the first contact with a diagnosis AF in the National Patient Register within the inclusion period. Diagnoses given from 1997 and up to the individual index date +30 days were used for characterization of the medical history. Diagnoses given after index date +30 days were used for identification of outcome events. Time at risk was counted from index date +30 days. Censoring was made at the specified event, at death or on 31 December 2012, whichever came first. Minimum follow‐up was 1 year.

Endpoints {#ehf212262-sec-0006}
---------

The primary endpoint was ischaemic stroke. Secondary endpoints were other thromboembolism (unspecified stroke and pulmonary and systemic embolism), intracranial haemorrhage, any other hospital contact for a bleeding event, and a composite endpoint consisting of ischaemic or haemorrhagic stroke or death.

Data sources {#ehf212262-sec-0007}
------------

The Patient Register contains detailed information about hospitalizations and visits to hospital affiliated outpatient clinics in Sweden but does not contain information about visits in primary care. More than 99% of all entries in the Patient Register are technically correct.[9](#ehf212262-bib-0009){ref-type="ref"} A diagnosis of AF at hospital discharge is correct in 97% of cases.[10](#ehf212262-bib-0010){ref-type="ref"} A diagnosis of heart failure made in a clinic of internal medicine or cardiology could retrospectively be verified on the basis of available documentation in 86% and 91% of the cases, respectively.[11](#ehf212262-bib-0011){ref-type="ref"} For most other diagnoses, the positive predictive values are in the range 85--95%.[12](#ehf212262-bib-0012){ref-type="ref"}

The Patient Register (<http://www.sos.se>) was used to obtain information needed for calculation of individual risk scores for ischaemic stroke and bleeding according to CHA~2~DS~2~‐VASc[1](#ehf212262-bib-0001){ref-type="ref"} and HAS‐BLED.[13](#ehf212262-bib-0013){ref-type="ref"} In the CHA~2~DS~2~‐VASc scheme, 2 points are given for previous stroke/transient ischaemic attack/systemic embolism, and for age ≥ 75 years and 1 point each for heart failure, hypertension, diabetes, vascular disease, female sex, and age 65--74 years. HAS‐BLED gives 1 point each for hypertension, renal disease, liver disease, previous stroke, history of major bleeding, age ≥ 65 years, concomitant treatment with drugs known to increase bleeding risk, alcohol abuse, and poorly controlled anticoagulant treatment. Because we did not have access to individual international normalized ratio values, all patients received zero points for this variable, and the HAS‐BLED score may therefore have been underestimated. The specific International Classification of Diseases‐10 codes used are listed in *Table* [*S1*](#ehf212262-supitem-0001){ref-type="supplementary-material"}.

Information about oral anticoagulants and other medication use was obtained from the Drug Register, which stores details about every filled prescription in Sweden since 1 July 2005. All pharmacies are required to participate by law. It says nothing about prescriptions that were issued but not filled or about over the counter medications. The only registered oral anticoagulant in Sweden during the study period was warfarin. Medication at baseline was defined by the presence of a filled prescription within 120 days before, up to 30 days after index date.

Patient level information about socio‐economic conditions such as education, income, and immigrant status, which may have affected decisions about anticoagulation, was obtained from the LISA register maintained by the governmental agency Statistics Sweden (<http://www.scb.se>).

Definition of heart failure {#ehf212262-sec-0008}
---------------------------

In the absence of echocardiographic data or information about the severity of heart failure, we used three different and increasingly broad definitions as sensitivity analyses in order to assess the robustness of the results.Heart failure definition 1 (CHF 1). A hospital discharge diagnosis of heart failure as principal or first secondary diagnosis and a filled prescription of a diuretic. Both within 3 months before index + 30 days.Heart failure definition 2 (CHF 2). A hospital discharge diagnosis of heart failure as principal or first secondary diagnosis within 1 year before index + 30 days.

Heart failure definition 3 (CHF 3). Any diagnosis of heart failure in open or in hospital care before index + 30 days.

This strictly defined CHF 1 heart failure has been used for the main results, with CHF 2 and CHF 3 for sensitivity analysis purposes only. 'No heart failure' refers to patients without heart failure according to any of these definitions.

Statistical methods {#ehf212262-sec-0009}
-------------------

Baseline characteristics were presented descriptively, and differences were tested with *t*‐test (two sided) and χ^2^ test. Incidences were calculated as events per 100 years at risk but expressed as percentages in the text for easier reference.

Endpoints were analysed using univariable and multivariable Cox regressions with stepwise inclusion of cofactors and with the Efron method for handling ties. A list of the cofactors used is presented in the footnote to *Table* [1](#ehf212262-tbl-0001){ref-type="table-wrap"}. The original CHA~2~DS~2~‐VASc score was calculated for each definition of heart failure (CHF 1--3) and compared with a 'HA~2~DS~2~‐VASc' score, that is without counting points for heart failure. Non‐parametric receiver operating characteristic analysis (receiver operator curves) and net reclassification improvement were calculated for the primary endpoint to assess concordance between model predictions and observed outcomes. *P* values \<0.05 were considered significant. Analyses were performed in Stata 14.0 (Stata Corp, College Station, TX 77845, USA).

###### 

Heart failure as predictor of outcomes

                                                                                                     CHF 1           CHF 2     CHF 3                                  
  ---------------------------------------------------------------------------------- --------------- ------------ ------------ ------------ ------------ ------------ ------------
  Ischaemic stroke                                                                   HF univariate   1.41          1.35--1.47  1.37         1.32--1.43   1.33         1.30--1.37
  \+ age and sex                                                                     0.98            0.94--1.03       1.00     0.96--1.04   1.01         0.98--1.04   
  \+ CHA~2~DS~2~‐VASc components                                                     0.98            0.93--1.02       0.98     0.94--1.02   0.97         0.94--1.00   
  \+ comorbidity and socio‐economy[a](#ehf212262-note-0005){ref-type="fn"}           0.97            0.95--1.04       1.00     0.96--1.04   0.97         0.94--1.00   
  \+ medication[b](#ehf212262-note-0006){ref-type="fn"}                              1.01            0.96--1.06       1.02     0.97--1.07   1.01         0.97--1.04   
  Other thromboembolism (unspecified stroke and peripheral and pulmonary embolism)   HF univariate   1.93          1.81--2.07  1.88         1.77--2.00   1.72         1.64--1.81
  \+ age and sex                                                                     1.41            1.31--1.51       1.42     1.33--1.51   1.34         1.28--1.41   
  \+ CHA~2~DS~2~‐VASc components                                                     1.36            1.27--1.46       1.37     1.28--1.46   1.28         1.21--1.34   
  \+ comorbidity and socio‐economy[a](#ehf212262-note-0005){ref-type="fn"}           1.28            1.19--1.38       1.28     1.20--1.37   1.20         1.14--1.26   
  \+ medication[b](#ehf212262-note-0006){ref-type="fn"}                              1.15            1.06--1.25       1.18     1.10--1.28   1.14         1.07--1.20   
  Intracranial haemorrhage                                                           HF univariate   1.31          1.20--1.42  1.26         1.17--1.36   1.24         1.18--1.31
  \+ age and sex                                                                     1.00            0.92--1.09       0.99     0.92--1‐07   1.01         0.95--1.06   
  \+ HAS‐BLED components                                                             1.00            0.92--1.09       0.99     0.92--1.07   0.98         0.92--1.03   
  \+ comorbidity and socio‐economy[a](#ehf212262-note-0005){ref-type="fn"}           1.00            0.91--1.09       1.01     0.90--1.07   0.98         0.93--1.04   
  \+ medication[b](#ehf212262-note-0006){ref-type="fn"}                              0.99            0.89--1.09       0.98     0.93--1.09   0.97         0.90--1.03   
  Other bleeding                                                                     HF univariate   2.02          1.96--2.09  1.96         1.90--2.02   1.87         1.83--1.92
  \+ age and sex                                                                     1.53            1.48--1.58       1.53     1.48--1.57   1.51         1.47--1.54   
  \+ HAS‐BLED components                                                             1.41            1.37--1.46       1.41     1.37--1.45   1.38         1.35--1.42   
  \+ comorbidity and socio‐economy[a](#ehf212262-note-0005){ref-type="fn"}           1.32            1.27--1.36       1.30     1.26--1.34   1.29         1.26--1.32   
  \+ medication[b](#ehf212262-note-0006){ref-type="fn"}                              1.14            1.10--1.19       1.15     1.11--1.20   1.17         1.14--1.21   
  Death from any cause                                                               HF univariate   3.21          3.16--3.26  3.03         2.98--3.07   2.60         2.57--2.63
  \+ age and sex                                                                     2.00            1.97--2.03       2.00     1.97--2.03   1.80         1.78--1.83   
  \+ comorbidity and socio‐economy[a](#ehf212262-note-0005){ref-type="fn"}           1.73            1.70--1.76       1.70     1.67--1.73   1.54         1.52--1.56   
  \+ medication[b](#ehf212262-note-0006){ref-type="fn"}                              1.45            1.42--1.48       1.47     1.45--1.50   1.36         1.34--1.37   
  Composite of ischaemic stroke, intracranial bleed, and death                       HF univariate   2.86          2.82--2.90  2.71         2.67--2.75   2.36         2.33--2.38
  \+ age and sex                                                                     1.83            1.80--1.86       1.83     1.80--1.86   1.66         1.64--1.68   
  \+ comorbidity and socio‐economy[a](#ehf212262-note-0005){ref-type="fn"}           1.61            1.59--1.64       1.59     1.56--1.61   1.44         1.42--1.46   
  \+ medication[b](#ehf212262-note-0006){ref-type="fn"}                              1.40            1.37--1.42       1.41     1.39--1.44   1.30         1.28--1.32   

CI, confidence interval; CHF, congestive heart failure; HF, heart failure; HR, hazard ratio.

Adjustment for heart failure, age (continuous), gender, previous stroke, venous thromboembolism, any previous diagnosis of bleeding, platelet or coagulation defect, anaemia, previous myocardial infarction, ischaemic heart disease without infarction, peripheral artery disease, valvular disease (not qualifying as exclusion criteria), pacemaker/implantable cardioverter defibrillator, hypertension, diabetes, renal failure, liver disease, hypothyroidism, thyrotoxicosis, chronic pulmonary disease, alcohol index, dementia, cancer within 3 years, income, education, living alone, and working.

Adjustment for baseline use of warfarin, aspirin, clopidogrel, noac, beta‐blockers, class I antiarrhythmic agents, class III antiarrhythmic agents, digoxin, verapamil or diltiazem, dihydropyridine calcium blockers, diuretics, aldosterone receptor blockers, angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers, statins and non steroidal anti‐inflammatory drugs, proton pump inhibitors, and selective serotonin reuptake inhibitors.

The study was approved by the regional ethics committee and conformed to the Declaration of Helsinki. Individual patient consent was not required or obtained.

Results {#ehf212262-sec-0010}
=======

During the 7.5 year study period, 300 839 patients with AF met the inclusion criteria. Of these, 34 773 (11.6%) had received a hospital discharge diagnosis of heart failure and also filled a prescription for a diuretic within the preceding 3 months (CHF 1), 44 334 (14.7%) had received a discharge diagnosis within the preceding year (CHF 2), and 92 532 (30.8%) had in one way or the other received a diagnosis of heart failure at any time before index date (CHF 3). There were 2462 men (4.9% of all), who had received their one and only point on the CHA~2~DS~2~‐VASc scale due to heart failure. Irrespective of definition, AF patients with heart failure were older, for example patients with CHF 1 were more than 7.5 years older than patients without (80.5 vs. 72.8 years, *P* \< 0.001), and had higher risk scores both for ischaemic stroke (CHA~2~DS~2~‐VASc 4.4 vs. 2.6, *P* \< 0.001) and bleeding (HAS‐BLED 2.6 vs. 2.1, *P* \< 0.001) than other patients (*Table* [2](#ehf212262-tbl-0002){ref-type="table-wrap"}). As expected, the use of diuretics, beta‐blockers, angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone antagonists was more common among patients with than without heart failure ([*Table S2*](#ehf212262-supitem-0001){ref-type="supplementary-material"}). Less than half of the patients used warfarin: crude rates 44.5% of those with, and 43.1% of those without, CHF 1 (*P* \< 0.001).

###### 

Baseline characteristics in relation to definition of heart failure

                                                                                             CHF 1       No CHF[a](#ehf212262-note-0002){ref-type="fn"}   *P*         CHF 2       CHF3
  ------------------------------------------------------------------ ----------------------- ----------- ------------------------------------------------ ----------- ----------- -------
  Age, mean (median)                                                 80.5 (82)               72.8 (75)   \<0.001                                          79.8 (82)   79.2 (81)   
  Women                                                              47.9%                   44.0%       \<0.001                                          46.4%       45.8%       
  Living alone                                                       68.7%                   51.1%       \<0.001                                          67.3%       64.2%       
  Annual income and/or pension after taxes, 1000 SEK mean (median)   162 (130)               189 (144)   \<0.001                                          164 (130)   165 (131)   
  University/college studies                                         29.4%                   26.0%       \<0.001                                          29.3%       27.2%       
  Immigrant                                                          10.6%                   10.4%       0.268                                            10.9%       10.8%       
  CHA~2~DS~2~‐VASc score, mean (median)                              4.4 (4)                 2.6 (3)     \<0.001                                          4.4 (4)     4.4 (4)     
  HAS‐BLED score, mean (median)                                      2.6 (3)                 2.1 (2)     \<0.001                                          2.6 (3)     2.6 (3)     
  Previous thromboembolism                                           Ischaemic stroke        14.0%       14.2%                                            0.394       14.5%       16.4%
  Unspecified stroke and systemic or pulmonary embolism              6.1%                    5.1%        \<0.001                                          6.2%        6.7%        
  Previous bleeding                                                  Intracranial            2.4%        2.4%                                             0.774       2.4%        2.7%
  Other                                                              14.9%                   9.2%        \<0.001                                          15.2%       15.6%       
  Anaemia                                                            10.6%                   4.4%        \<0.001                                          10.8%       9.4%        
  Platelet or coagulation defect                                     1.0%                    0.8%        \<0.001                                          1.1%        1.1%        
  Ischaemic heart disease                                            Myocardial infarction   30.4%       12.5%                                            \<0.001     31.3%       31.3%
  w/o myocardial infarction                                          15.2%                   11.4%       \<0.001                                          15.5%       17.1%       
  Peripheral arterial disease                                        9.7%                    5.4%        \<0.001                                          9.9%        10.2%       
  Valvular disease (other than exclusion criteria)                   15.5%                   6.2%        \<0.001                                          15.4%       15.0%       
  Pacemaker or ICD                                                   10.3%                   6.5%        \<0.001                                          11.3%       12.0%       
  Hypertension                                                       51.8%                   46.4%       \<0.001                                          51.6%       53.5%       
  Diabetes                                                           23.5%                   13.7%       \<0.001                                          23.5%       23.8%       
  Renal failure                                                      11.2%                   2.6%        \<0.001                                          11.2%       9.7%        
  Liver disease                                                      1.3%                    0.9%        \<0.001                                          1.4%        1.4%        
  Thyroid disease                                                    Hypo                    5.0%        3.3%                                             \<0.001     5.0%        4.6%
  Hyper                                                              0.7%                    0.8%        0.012                                            0.7%        0.8%        
  Chronic obstructive pulmonary disease                              12.8%                   4.9%        \<0.001                                          13.2%       12.7%       
  Alcohol index[b](#ehf212262-note-0003){ref-type="fn"}              2.2%                    2.4%        0.016                                            2.4%        2.5%        
  Dementia                                                           4.7%                    3.3%        \<0.001                                          4.7%        5.2%        
  Cancer within 3 years                                              14.2%                   13.9%       0.257                                            14.5%       15.4%       

CHF, congestive heart failure; ICD, implantable cardioverter defibrillator.

In the no CHF group, patients with heart failure according to all three definitions were excluded.

'Alcohol index' is a set of diagnostic codes used by the Swedish Board of Health and Welfare for annual reporting of alcohol‐related mortality (International Classification of Diseases‐10 codes).

The primary endpoint: ischaemic stroke {#ehf212262-sec-0011}
--------------------------------------

The 1 year incidences of ischaemic stroke among AF patients without warfarin were 4.4%, 4.3%, and 4.1% with CHF 1--3, respectively, and 3.1% among patients without any previous diagnosis of heart failure. Among patients with warfarin at baseline, the corresponding incidences were 1.7%, 1.7%, and 1.8% with CHF 1--3 and 1.5% among patients without heart failure.

Adjustment for the cofactors in CHA~2~DS~2~‐VASc eradicated the difference in ischaemic stroke risk between patients with and without heart failure \[hazard ratio (HR) 0.98 with 95% confidence interval (CI) 0.93--1.02\] (*Figure* [*2*](#ehf212262-fig-0002){ref-type="fig"}). The results were similar with all three definitions of heart failure (*Table* [1](#ehf212262-tbl-0001){ref-type="table-wrap"}).

![Forest plot showing the association between congestive heart failure (CHF 1) and outcome among 300 839 patients with atrial fibrillation. Multivariable adjustments to the hazard ratio (HR) and corresponding 95% confidence interval (CI) with stepwise inclusion of cofactors.](EHF2-5-231-g002){#ehf212262-fig-0002}

Secondary endpoints {#ehf212262-sec-0012}
-------------------

Our secondary endpoint '*other thromboembolism*', which did not count ischaemic stroke but counted unspecified stroke (which also may be haemorrhagic) and pulmonary and systemic embolism, occurred more often in patients with heart failure. The 1 year incidences among AF patients without warfarin were 1.9%, 1.9%, and 1.7% with CHF 1--3 and 1.0% among patients without heart failure.

The unadjusted HR for such other thromboembolism with heart failure was 1.93 (95% CI 1.81--2.07) compared with no heart failure (*Figures* [*2*](#ehf212262-fig-0002){ref-type="fig"} and [*3*](#ehf212262-fig-0003){ref-type="fig"}). Adjustment for CHA~2~DS~2~‐VASc did not neutralize this excess risk. After adjustment for 45 cofactors including comorbidity, medication, and socio‐economic conditions, patients with heart failure still were at higher risk than patients without heart failure (HR 1.15, 95% CI 1.06--1.25). The results were similar with our more inclusive definitions of heart failure (*Table* [3](#ehf212262-tbl-0003){ref-type="table-wrap"}).

![Incidence of ischaemic stroke among 300 839 patients with atrial fibrillation in relation to heart failure and warfarin use at baseline; CHF definition 1. CHF, congestive heart failure; OAC, oral anticoagulation.](EHF2-5-231-g003){#ehf212262-fig-0003}

###### 

Predictive efficacy of CHA~2~DS~2~‐VASc with and without points for heart failure. Only patients not on warfarin

   Ischaemic stroke within 1 year                                                                             
  -------------------------------- ------------------------ -------------- -------------- ------- ----------- -------
              ≥1 point             CHF 1 CHA~2~DS~2~‐VASc   0.542          0.540--0.543   0.031   0.996       0.001
       CHF 2 CHA~2~DS~2~‐VASc      0.541                    0.539--0.543   0.031          0.996   0.001       
       CHF 3 CHA~2~DS~2~‐VASc      0.535                    0.533--0.536   0.032          0.996   −0.002      
          HA~2~DS~2~‐VASc          0.536                    0.533--0.536   0.032          0.995   Reference   
             ≥2 points             CHF 1 CHA~2~DS~2~‐VASc   0.587          0.583--0.590   0.035   0.993       0.023
       CHF 2 CHA~2~DS~2~‐VASc      0.584                    0.580--0.587   0.035          0.993   0.017       
       CHF 3 CHA~2~DS~2~‐VASc      0.572                    0.569--0.575   0.035          0.993   −0.016      
          HA~2~DS~2~‐VASc          0.575                    0.572--0.578   0.035          0.993   Reference   
             Continuous            CHF 1 CHA~2~DS~2~‐VASc   0.638          0.631--0.646   n/a                 
       CHF 2 CHA~2~DS~2~‐VASc      0.633                    0.626--0.641                                      
       CHF 3 CHA~2~DS~2~‐VASc      0.620                    0.613--0.627                                      
          HA~2~DS~2~‐VASc          0.628                    0.622--0.635                                      

CI, confidence interval; n/a, not applicable.

CHF 1. A hospital discharge diagnosis of heart failure as principal or first secondary diagnosis and a filled prescription of a diuretic. Both within 3 months before index + 30 days.

CHF 2. A hospital discharge diagnosis of heart failure as principal or first secondary diagnosis within 1 year before index + 30 days.

CHF 3. Any diagnosis of heart failure in open or in hospital care before index + 30 days.

The 1 year incidence *extracranial bleedings* were more common among heart failure patients than among patients without heart failure (6.5% vs. 3.8%, *P* \< 0.001). The excess bleeding risk associated with heart failure remained after adjustment for cofactors (HR 1.14, 95% CI 1.10--1.19). Regarding *intracranial haemorrhages*, no difference was seen in relation to heart failure (HR 0.99, 95% CI 0.89--1.09).

Heart failure patients more often met the *composite endpoint* of stroke (regardless of cause) and death than other patients. This was mostly driven by mortality component, which was three times higher (unadjusted) among heart failure patients. The annualized rates among patients with and without heart failure were 25.0% and 7.5%, respectively (*P* \< 0.001). This difference between patients with and without heart failure remained after multivariable adjustment (HR 1.40, 95% CI 1.37--1.42) (*Table* [1](#ehf212262-tbl-0001){ref-type="table-wrap"}). Among patients with heart failure, those who used warfarin at baseline more seldom met the composite endpoint than heart failure patients without warfarin (HR 0.72, 95% CI 0.70--74). The apparent benefit of warfarin treatment was similar in the control population of patients without heart failure (HR 0.68, 95% CI 0.66--0.69).

Points for heart failure in CHA~2~DS~2~‐VASc {#ehf212262-sec-0013}
--------------------------------------------

We calculated CHA~2~DS~2~‐VASc scores without giving points for heart failure, that is 'HA~2~DS~2~‐VASc' scores, and compared its ability to predict ischaemic stroke with CHA~2~DS~2~‐VASc scores calculated with the three different definitions of heart failure (*Table* [3](#ehf212262-tbl-0003){ref-type="table-wrap"}). With a cut‐off limit for high risk at ≥2 points, both the old and the new scheme had the same negative predictive value of 0.993, meaning that a patient with a low score of 0--1 points have an annual risk of ischaemic stroke of 0.7% irrespective of whether points are counted for heart failure or not. The positive predictive values were low for both schemes (0.035) indicating that the schemes are extremely poor in predicting who will actually suffer an ischaemic stroke. The area under the receiver operating characteristic curve was marginally better with CHA~2~DS~2~‐VASc (0.587, 95% CI 0.583--0.590) than with HA~2~DS~2~‐VASc (0.575, 95% CI 0.572--0.578) if the restrictive definition of heart failure was used, that is only counting heart failure diagnoses with recent hospitalizations as primary or first secondary diagnoses and with baseline use of diuretics (*Table* [3](#ehf212262-tbl-0003){ref-type="table-wrap"}). If any previous diagnosis of heart failure in the medical history was considered when counting points for CHA~2~DS~2~‐VASc, it performed no better than HA~2~DS~2~‐VASc (c‐statistic 0.572, 95% CI 0.569--0.575). With this inclusive definition of heart failure (CHF 3), the net reclassification improvement of using CHA~2~DS~2~‐VASc over HA~2~DS~2~‐VASc even tended to be negative (*Table* [3](#ehf212262-tbl-0003){ref-type="table-wrap"}).

Discussion {#ehf212262-sec-0014}
==========

To date, this is the largest and most comprehensively adjusted analysis of stroke risk in AF patients with heart failure. The results suggest that a clinical diagnosis of heart failure is not a valid independent risk factor for stroke among these patients. This finding may be highly relevant for those 5% of the male AF population who have received their only CHA~2~DS~2~‐VASc point due to heart failure (*Figure* [*3*](#ehf212262-fig-0003){ref-type="fig"}).

Although we performed adjustment for extensive covariates, heart failure lost its association with stroke already after adjustment for age, gender, and the CHA~2~DS~2~‐VASc components. The most common causes for heart failure are hypertension, ischaemic heart disease, diabetes, and age, which already are included in the CHA~2~DS~2~‐VASc scheme. Adding heart failure to the score therefore adjusts for what has already been adjusted for. It is true that heart failure patients are at higher risk of stroke than patients without heart failure, but this can thus be accounted for by age comorbidity.

It may be questioned if it is meaningful to count points for heart failure in the CHA~2~DS~2~‐VASc scheme. However, the CHA~2~DS~2~‐VASc score is ingrained in clinical practice and likely facilitates appropriate use of oral anticoagulants. Tampering with new acronyms in order to maximize the predictive power of the risk score schemes may cause confusion and abandonment of structured risk assessment all together.

We however propose that physicians recognize that 'heart failure' is a weak point in in the CHA~2~DS~2~‐VASc scheme, which only should be used for patients with recent and severe incompensation. Just any mentioning of heart failure in the medical records is not enough. This proposal however requires further studies, preferably with echocardiographic data.

Our results confirm the findings in some studies[3](#ehf212262-bib-0003){ref-type="ref"}, [6](#ehf212262-bib-0006){ref-type="ref"}, [14](#ehf212262-bib-0014){ref-type="ref"} and contradict the results of others,[15](#ehf212262-bib-0015){ref-type="ref"}, [16](#ehf212262-bib-0016){ref-type="ref"}, [17](#ehf212262-bib-0017){ref-type="ref"} as in a study of 6438 patients in Tours in France where the risk of thromboembolism was doubled in heart failure (HR 2.16, 95% CI (1.20--3.90).[15](#ehf212262-bib-0015){ref-type="ref"} It is, however, difficult to make comparisons between these studies because differences in patient selection and design. For example, the Tours study classified 51.4% of the patients as heart failure compared with 11.6% in our study. Furthermore, while heart failure did not appear to independently increase the risk of stroke, oral anticoagulation was nevertheless effective in reducing stroke in patients with heart failure, as expected. Many patients with heart failure will have other risk factors and clear indications for anticoagulation regardless of presence of heart failure.

Limitations {#ehf212262-sec-0015}
-----------

A limitation of our study is that we were dependent on the diagnostic codes given by doctors all over the country, without possibility to validate data by scrutiny of random samples of medical records and examinations because we only had access to anonymized data. However, previous validation studies have shown that it is possible to verify a heart failure diagnosis retrospectively in approximately 90% of the cases.[11](#ehf212262-bib-0011){ref-type="ref"}, [12](#ehf212262-bib-0012){ref-type="ref"} An even higher proportion of diagnoses may be correct, although the documentation is no longer available.

We had no access to echocardiographic data. In previous studies, heart failure has been defined in many different ways, both with and without use of echocardiographic data.[7](#ehf212262-bib-0007){ref-type="ref"}, [8](#ehf212262-bib-0008){ref-type="ref"} The results of studies using echocardiographic studies have not differed markedly from studies not doing so. We did not have access to severity of heart failure. Heart failure is a clinical diagnosis, which includes both patients with reduced and preserved ejection fraction, often called diastolic heart failure. Previous studies suggest that 1/3 to 1/2 of all heart failure patients have preserved ejection fraction.[18](#ehf212262-bib-0018){ref-type="ref"}, [19](#ehf212262-bib-0019){ref-type="ref"} Hypothetically, if heart failure with reduced ejection confers increased stroke risk, and heart failure with preserved ejection does not (or vice versa for that matter), our inability to differentiate between these conditions could have obscured the results.

We cannot rule out the possibility that severe heart failure with recent decompensation or conversely, longer duration heart failure with more remodelling, may increase thromboembolic risk. Nor were we able to account for new‐onset heart failure during follow‐up in the control group, which may have biased the results towards the null. Our sensitivity analyses did however not show any important differences in the results whether only hospitalizations within the preceding 3 months, with the diagnosis as principal or first secondary position, and concomitant treatment with diuretics or if previous diagnosis of heart failure at any time was used.

Register studies are in general prone to underestimate risk factors that have not been diagnosed, and despite large and unselective population and extensive covariate adjustment, any risk factors or treatment effects remain associations only.

Under‐diagnosis is much more common than overdiagnosis. Thus, assessment of individual risk scores from register data is likely to give lower scores than the true situation. The extent of under‐diagnosis is largely unknown because assessment requires screening of the general population and in addition is likely to change over time.

Any registry is subject to bias and confounding, which limits interpretation of treatment effects in particular. With regard to warfarin use, confounding by indication is often a problem. Patients with poor compliance or short life expectancy may have been less likely to receive warfarin. Such circumstances are often not reflected by codes or data in registers.

Our information about exposure to warfarin assumes that all patients who purchased warfarin also used it, which rarely is the case. The treated share of patients is therefore most likely even lower than our estimates. However, we analysed warfarin use at baseline only, in analogy to intention to treat analysis, and any crossover during follow‐up would dilute the benefits that we observed.

Finally, in patients with AF, all ischaemic strokes are not cardioembolic, which limits the ability to detect specifically AF‐related cardioembolism.

Conclusions {#ehf212262-sec-0016}
===========

A clinical diagnosis of heart failure was not an independent risk factor for stroke in patients with AF. The role of heart failure in CHA~2~DS~2~‐VASc requires further investigation.
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